Active KRAS Lung Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a KRAS-Mutated Lung Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting KRAS-Mutated Lung Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your KRAS-Mutated Lung Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

KRAS-Mutated Lung Cancer Clinical Trial FAQ

What KRAS G12C trials are currently available for lung cancer?

KRAS G12C inhibitors sotorasib (Lumakras) and adagrasib (Krazati) are FDA-approved for previously treated KRAS G12C NSCLC. Trials are testing these agents in first-line settings, in combination with checkpoint inhibitors or MEK inhibitors to overcome resistance, and next-generation G12C inhibitors designed to be more potent or to address acquired resistance mechanisms (Y96D, H95 mutations).

Are there clinical trials for KRAS G12D or G12V lung cancer?

Yes — and this is an active frontier. KRAS G12C-specific inhibitors don't work against G12D or G12V variants. Trials are testing pan-KRAS inhibitors that target multiple KRAS variants, G12D-specific inhibitors, and neoantigen vaccines targeting KRAS G12D peptides. Several bispecific antibodies and cell therapies targeting KRAS-mutant epitopes are also in early trials.

What is SOS1 or SHP2 inhibition, and how does it relate to KRAS lung cancer trials?

SOS1 and SHP2 are proteins that activate KRAS and other RAS-family proteins. SOS1 inhibitors (BI 1701963) and SHP2 inhibitors (TNO155, RMC-4630) are being combined with KRAS G12C inhibitors in trials to prevent resistance by blocking KRAS signaling from a different angle. These combinations aim to keep KRAS G12C inhibitors effective longer.

How is KRAS mutation status determined for lung cancer?

KRAS mutation status is determined by molecular profiling of your tumor tissue (biopsy or surgical specimen) using next-generation sequencing (NGS) or PCR-based tests. Liquid biopsy (blood-based ctDNA testing) can also detect KRAS mutations, though tissue testing remains more sensitive. All patients with advanced NSCLC should have comprehensive molecular testing — including KRAS variant subtype — before starting treatment.

Does having a KRAS mutation affect my eligibility for immunotherapy trials in lung cancer?

KRAS G12C co-mutation with STK11 or KEAP1 is associated with lower response to immunotherapy. Several trials are specifically designed for KRAS-mutated NSCLC patients with STK11/KEAP1 co-mutations, who have the greatest unmet need. Knowing your co-mutation status can help identify trials where novel combinations are being tested to overcome immunotherapy resistance.

Explore Other Cancer Trial Guides

• Non-Small Cell Lung Cancer (NSCLC) — Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, representing about 85% of all cases. Trials are testing EGFR, ALK, KRAS, MET, and RET targeted therapies alongside checkpoint immunotherapy for all stages of NSCLC.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Pancreatic Cancer — Pancreatic cancer trials are at the forefront of KRAS inhibitor research, mRNA vaccines, and combination immunotherapy. Participating in a trial may give access to treatments not yet available to the general public.